| A perspective on multi-target drug discovery and design for complex diseases RR Ramsay, MR Popovic-Nikolic, K Nikolic, E Uliassi, ML Bolognesi Clinical and translational medicine 7, 1-14, 2018 | 671 | 2018 |
| Multitarget drug design strategy: quinone–tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects E Nepovimova, E Uliassi, J Korabecny, LE Pena-Altamira, S Samez, ... Journal of medicinal chemistry 57 (20), 8576-8589, 2014 | 192 | 2014 |
| The Hippo pathway and YAP/TAZ–TEAD protein–protein interaction as targets for regenerative medicine and cancer treatment: Miniperspective M Santucci, T Vignudelli, S Ferrari, M Mor, L Scalvini, ML Bolognesi, ... Journal of medicinal chemistry 58 (12), 4857-4873, 2015 | 182 | 2015 |
| Sustainable production of pharmaceutical, nutraceutical and bioactive compounds from biomass and waste C Espro, E Paone, F Mauriello, R Gotti, E Uliassi, ML Bolognesi, ... Chemical Society Reviews 50 (20), 11191-11207, 2021 | 149 | 2021 |
| Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease J Jeřábek, E Uliassi, L Guidotti, J Korábečný, O Soukup, V Sepsova, ... European Journal of Medicinal Chemistry 127, 250-262, 2017 | 116 | 2017 |
| Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease K Chalupova, J Korabecny, M Bartolini, B Monti, D Lamba, R Caliandro, ... European journal of medicinal chemistry 168, 491-514, 2019 | 104 | 2019 |
| Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases F Prati, E Uliassi, ML Bolognesi MedChemComm 5 (7), 853-861, 2014 | 89 | 2014 |
| From companion diagnostics to theranostics: a new avenue for alzheimer’s disease? Miniperspective ML Bolognesi, A Gandini, F Prati, E Uliassi Journal of Medicinal Chemistry 59 (17), 7759-7770, 2016 | 66 | 2016 |
| Toward the development of dual‐targeted glyceraldehyde‐3‐phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi F Belluti, E Uliassi, G Veronesi, C Bergamini, M Kaiser, R Brun, A Viola, ... ChemMedChem 9 (2), 371-382, 2014 | 63 | 2014 |
| Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists A Junker, R Balasubramanian, A Ciancetta, E Uliassi, E Kiselev, ... Journal of Medicinal Chemistry 59 (13), 6149-6168, 2016 | 46 | 2016 |
| Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display … E Uliassi, G Fiorani, RL Krauth-Siegel, C Bergamini, R Fato, G Bianchini, ... European Journal of Medicinal Chemistry 141, 138-148, 2017 | 37 | 2017 |
| Enriching proteolysis targeting chimeras with a second modality: When two are better than one A Salerno, F Seghetti, J Caciolla, E Uliassi, E Testi, M Guardigni, ... Journal of Medicinal Chemistry 65 (14), 9507-9530, 2022 | 32 | 2022 |
| A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med 7: 3 RR Ramsay, MR Popovic-Nikolic, K Nikolic, E Uliassi, ML Bolognesi | 31 | 2018 |
| Discovery of Sustainable Drugs for Neglected Tropical Diseases: Cashew Nut Shell Liquid (CNSL)‐Based Hybrids Target Mitochondrial Function and ATP Production in Trypanosoma brucei M Cerone, E Uliassi, F Prati, GU Ebiloma, L Lemgruber, C Bergamini, ... ChemMedChem 14 (6), 621-635, 2019 | 27 | 2019 |
| Design, synthesis, pharmacological characterization of a fluorescent agonist of the P2Y14 receptor E Kiselev, R Balasubramanian, E Uliassi, KA Brown, K Trujillo, V Katritch, ... Bioorganic & medicinal chemistry letters 25 (21), 4733-4739, 2015 | 25 | 2015 |
| Accelerating drug discovery efforts for trypanosomatidic infections using an integrated transnational academic drug discovery platform CB Moraes, G Witt, M Kuzikov, B Ellinger, T Calogeropoulou, KC Prousis, ... SLAS DISCOVERY: Advancing Life Sciences R&D 24 (3), 346-361, 2019 | 24 | 2019 |
| Cashew nut shell liquid (CNSL) as a source of drugs for Alzheimer’s disease E Uliassi, AS de Oliveira, L de Camargo Nascente, LAS Romeiro, ... Molecules 26 (18), 5441, 2021 | 22 | 2021 |
| A focused library of psychotropic analogues with neuroprotective and neuroregenerative potential E Uliassi, LE Peña-Altamira, AV Morales, F Massenzio, S Petralla, ... ACS Chemical Neuroscience 10 (1), 279-294, 2018 | 22 | 2018 |
| Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery E Uliassi, A Gandini, RC Perone, ML Bolognesi Future medicinal chemistry 9 (10), 995-1013, 2017 | 21 | 2017 |
| Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer’s Disease L Gorecki, E Uliassi, M Bartolini, J Janockova, M Hrabinova, V Hepnarova, ... ACS Chemical Neuroscience 12 (9), 1698-1715, 2021 | 20 | 2021 |
